查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1987233

良性前列腺增生（BPH）治療市場規模、佔有率、趨勢和預測：按治療方法和地區分類，2026-2034年

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球良性前列腺增生（BPH）治療市場規模預估為130億美元。展望未來，IMARC Group預測，該市場將以4.09%的複合年成長率（CAGR）從2026年成長至2034年，到2034年達到189億美元。目前，北美市場是主要驅動力，預計2025年將佔據超過34.8%的市場。推動該市場成長的因素包括老年男性BPH盛行率的上升、微創手術技術的進步以及藥物製劑的改進。雷射療法和聯合治療的創新進一步改善了患者的治療效果，並促進了BPH治療市場佔有率的擴大。

良性攝護腺增生 (BPH) 治療市場的主要促進因素包括：老年男性族群中 BPH 盛行率的不斷上升、人們對泌尿器官系統健康的日益重視以及微創治療方法的進步。 BPH 對生活品質的影響，包括泌尿道症狀和併發症，推動了對有效治療方法的需求。雷射療法、改良的藥物配方和聯合治療等創新技術，以及已開發地區醫療保健服務的改善和有利的報銷政策，也促進了市場成長。例如，2024 年 9 月，皇家薩裡郡國民醫療服務體系基金會 (Royal Surrey NHS Foundation Trust) 推出了 EchoLaser 治療良性前列腺增生的方法，該疾病影響著大約 50% 的 50 歲以上男性。這項由慈善機構「前列腺計畫」(Prostate 計劃) 資助的微創手術，由於其恢復快、副作用小，能夠改善患者的生活品質並縮短住院時間。這些進展為 BPH 治療市場帶來了光明的前景。

在美國，良性前列腺增生（BPH）治療市場的主要促進因素是BPH在老齡男性群體中的高發病率以及人們對泌尿器官系統健康的日益關注。微創手術（例如雷射療法和前列腺動脈栓塞術）因其高效性和較短的恢復時間而越來越受歡迎。例如，2023年7月，波特蘭基督復臨安息日會醫療中心推出了水動力療法，這是一種利用水和機器人技術的微創BPH治療方法。這項創新治療方法為受BPH症狀困擾的男性提供了一種新的選擇。此外，改良的藥物和聯合治療也陸續問世，進一步擴展了治療方法選擇。這構成了美國BPH治療的主要趨勢之一。

良性攝護腺增生治療市場趨勢：

向微創手術過渡

微創手術在良性前列腺增生（BPH）的治療中日益普及。根據美國國立衛生研究院（NIH）統計，約30%的中重度BPH患者接受了某種形式的微創治療。這些技術包括雷射療法、經尿道微波熱療（TUMT）和經尿道前列腺切除術（TURP）。由於恢復時間短且療效顯著，這些手術方法被患者和醫生廣泛接受。此類手術方法最大限度地減少了對周圍組織的損傷，並能精準地標靶治療部位，從而降低了出血和感染疾病等併發症的發生率。此外，與傳統開放性手術相比，微創手術能減輕患者的疼痛，並使其更快恢復日常生活。這與醫療保健領域向微創、以門診為中心的醫療服務模式發展的總體趨勢相符。鈥雷射剜除術和綠光雷射療法等技術的進步進一步加速了這一市場轉變，為不願接受長期住院或侵入性手術的患者提供了新的治療方法選擇。隨著人們對這些治療方法的接受度不斷提高，預計未來良性前列腺增生症治療市場的需求將會增加。

先進藥物療法的出現

隨著新型藥物療法的出現，良性前列腺增生症 (BPH) 的治療模式正在發生巨大變化。新型藥物和聯合治療旨在更有效地控制症狀，同時減少副作用。根據美國國家糖尿病、胃腸病和腎臟疾病研究所 (NIDDK) 統計，51 至 60 歲男性中約有 50% 患有 BPH，80 歲以上男性中這一比例高達 90%，這凸顯了藥物治療方案日益成長的需求。雖然傳統的治療方法，例如 α 受體阻斷劑和 5α 還原酶抑制劑 (5-ARI) 仍然發揮著重要作用，但這些先進的藥物治療方法雖然常用，卻也伴隨著一些顯著的副作用，例如頭暈和性功能障礙。 Avodart 和 Cialis 等藥物專利的到期為學名藥進入市場創造了機會，提供了價格更實惠的替代方案，並推動了藥物治療市場的發展。 PDE5 抑制劑和新型雙標靶療法等藥物的研發投入不斷增加，為緩解症狀提供了更全面的途徑。這些先進藥物不僅能治療攝護腺疾病，還能治療勃起功能障礙—良性攝護腺增生症 (BPH) 的常見併發症。隨著更多治療方法的出現，患者將能夠採用更適合自身健康狀況和症狀的個人化、症狀導向治療方案。此外，合併用藥以提高療效並最大限度減少有害副作用也成為一種趨勢。隨著生物製藥和基因療法進入臨床試驗並最終應用於臨床，為患者提供有效的長期治療，BPH 的治療模式預計將發生更顯著的變化。

老年人口增加

全球老年人口是良性前列腺增生（BPH）治療市場的主要成長要素。 BPH的發生率老齡化增加，50歲以上男性最為常見。 1974年至2024年間，全球65歲及以上人口的比例幾乎加倍，從5.5%增加到10.3%。根據聯合國人口預測，預計2024年至2074年間，這一比例將再次翻番，達到20.7%。同時，80歲及以上人口預計將增加三倍以上。已開發地區的老年人口預計將顯著成長，導致需要接受BPH治療的人大幅增加。這種人口結構變化可能會給醫療保健系統帶來額外負擔，因此需要有效且價格合理的治療性介入。全球老化正在推動對BPH治療的需求，而學名藥透過提供更低成本的選擇，提高了患者的用藥可及性，並促進了醫療保健產品的銷售。老年男性更容易罹患高血壓和糖尿病等合併症。這些合併症進一步增加了良性攝護腺增生症（BPH）的治療難度，因此需要製定能夠同時滿足多種健康需求的個人化治療方法。老年人更容易出現BPH治療的副作用，例如頭暈和跌倒風險增加。隨著人口老化，透過更安全的治療方法最大限度地降低這些風險已成為醫療保健的重中之重。因此，製藥和醫療保健相關企業一直在研發治療BPH症狀並改善患者整體生活品質的藥物，尤其關注老年患者。預計老齡人口將持續成長，這將透過增加對藥物和手術治療方法的需求來影響市場。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球良性前列腺增生治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 藥物類別
    • 主要類型
      • α受體阻斷劑
      • 5α-還原酶抑制劑（5-ARIs）
      • 磷酸二酯酶-5抑制劑
      • 其他
  • 微創手術
    • 主要類型
      • 經尿道前列腺切除術（TURP）
      • 經尿道前列腺切開術（TUIP）
      • 經尿道微波熱療（TUMT）
      • 機器人手術
      • 前列腺尿道提升術
      • 其他
  • 雷射療法
  • 其他

第7章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第8章 SWOT 分析

第9章：價值鏈分析

第10章：波特五力分析

第11章：價格分析

第12章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Allergan plc（AbbVie Inc.）
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH（CH Boehringer Sohn AG & Ko. KG）
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2898

The global benign prostatic hyperplasia treatment market size was valued at USD 13.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 18.9 Billion by 2034, exhibiting a CAGR of 4.09% during 2026-2034. North America currently dominates the market, holding a significant share of over 34.8% in 2025 . The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.

Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.

The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.

BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET TRENDS:

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.

Emergence of Advanced Drug Therapies

The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.

Rising Geriatric Population

The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.

BENIGN PROSTATIC HYPERPLASIA TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

  • Drug Class
    • Alpha-Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally Invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Robotic Surgeries
    • Prostatic Urethral Lifts
    • Others
  • Laser Therapy

Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

In 2025, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.

EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.

ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.

LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.

MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.

COMPETITIVE LANDSCAPE:

The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.

The report provides a comprehensive analysis of the competitive landscape in the benign prostatic hyperplasia treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan Plc (AbbVie Inc.)
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
  • Boston Scientific Corporation
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the benign prostatic hyperplasia treatment market?

2. What are the market drivers for benign prostatic hyperplasia (BHP) treatment devices?

3. What is the benign prostatic hyperplasia (BPH) treatment device market growth?

4. What are the key factors driving the benign prostatic hyperplasia treatment market?

5. Which region accounts for the largest benign prostatic hyperplasia treatment market share?

6. Which are the leading companies in the global benign prostatic hyperplasia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2025
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2025
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players